OPGN vs. ACON, BGLC, PMD, TTOO, DMTK, XGN, ADIL, CELZ, YMTX, and TTNP
Should you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Aclarion (ACON), BioNexus Gene Lab (BGLC), Psychemedics (PMD), T2 Biosystems (TTOO), DermTech (DMTK), Exagen (XGN), Adial Pharmaceuticals (ADIL), Creative Medical Technology (CELZ), Yumanity Therapeutics (YMTX), and Titan Pharmaceuticals (TTNP). These companies are all part of the "medical" sector.
OpGen (NASDAQ:OPGN) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, community ranking, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.
2.7% of OpGen shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 1.3% of OpGen shares are held by company insiders. Comparatively, 22.3% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
OpGen has a net margin of -852.18% compared to Aclarion's net margin of -6,480.47%. OpGen's return on equity of -316.30% beat Aclarion's return on equity.
OpGen has a beta of -0.56, suggesting that its share price is 156% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
OpGen received 300 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 55.84% of users gave OpGen an outperform vote.
Aclarion has lower revenue, but higher earnings than OpGen.
In the previous week, Aclarion had 1 more articles in the media than OpGen. MarketBeat recorded 4 mentions for Aclarion and 3 mentions for OpGen. Aclarion's average media sentiment score of 0.69 beat OpGen's score of 0.62 indicating that Aclarion is being referred to more favorably in the news media.
Summary
Aclarion beats OpGen on 8 of the 13 factors compared between the two stocks.
Get OpGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
